USPSTF, April 11, 2018, We strongly support the efforts of the USPSTF to draft a research plan to identify benefits and harms of tobacco cessation interventions in broad populations, including pregnant women. We encourage the USPSTF to consider: 1. the necessary evidence to establish the short-term and long-term benefits of tobacco cessation on an individual and population level 2. potential fetal outcomes, including developmental and birth-related outcomes. 3. the harms associated with electronic nicotine delivery systems, as these products have been touted as safer alternatives that may also serve as quit aids.
Read More »On Health Policy
Comments by Diana Zuckerman, Ph.D. on the U.S. Consumer Product Safety Commission Agenda and Priorities for FY2019-20
April 11, 2018. Endocrine disruptors and chemicals in common consumer products that do not stay bound to those products get into the air and dust and thus into our bodies. These chemicals tend to pose greater risks to fetuses and children, and there are large gaps in our knowledge about the chemicals in the products on the market.
Read More »Coalition Letter Calling for HHS Investigation of NIH Alcohol Study Funding
April 11, 2018. An independent investigation by the HHS Inspector General is necessary to ensure public confidence in the integrity of the investigation and that all culpable NIH officials are held accountable.
Read More »NCHR Letter to the Senate on Right To Try
March 23, 2018. We are writing to urge you to vote against the Right to Try bill that recently passed the House of Representatives (HR 5247) despite strong opposition from the Democratic leadership. Although HR 5247 includes some potentially useful requirements that the results of patients’ access to experimental drugs be made available to the FDA, so that they will be aware of serious harm that could be caused, there is no enforcement mechanism to make sure that information is made available.
Read More »Right To Try Fact Sheet
The Right to Try bill creates a program that is not as good as the existing FDA “Expanded Access” program, which has approved 99% of requests they received.
Read More »